Twist Bioscience (NASDAQ:TWST) Price Target Raised to $48.00

Twist Bioscience (NASDAQ:TWST) had its target price upped by Robert W. Baird from $46.00 to $48.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other brokerages have also recently weighed in on TWST. Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Barclays cut their target price on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. Finally, Leerink Partners upped their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $51.78.

Twist Bioscience Stock Up 1.9 %

NASDAQ TWST opened at $41.89 on Tuesday. The stock has a market capitalization of $2.49 billion, a PE ratio of -11.57 and a beta of 1.78. The company has a 50 day moving average price of $43.93 and a two-hundred day moving average price of $46.15. Twist Bioscience has a 12-month low of $23.07 and a 12-month high of $60.90.

Insider Transactions at Twist Bioscience

In related news, Director Robert Chess sold 3,600 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00. Following the transaction, the director now owns 21,641 shares in the company, valued at $1,022,753.66. This represents a 14.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dennis Cho sold 659 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $41.56, for a total transaction of $27,388.04. Following the transaction, the insider now owns 94,481 shares in the company, valued at approximately $3,926,630.36. This trade represents a 0.69 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. State Street Corp lifted its position in Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares during the period. Geode Capital Management LLC raised its position in shares of Twist Bioscience by 1.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock valued at $61,807,000 after acquiring an additional 26,145 shares during the period. Thrivent Financial for Lutherans acquired a new stake in shares of Twist Bioscience in the 3rd quarter valued at approximately $43,992,000. Wellington Management Group LLP raised its position in shares of Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares during the period. Finally, Fred Alger Management LLC raised its position in shares of Twist Bioscience by 17.1% in the 3rd quarter. Fred Alger Management LLC now owns 767,149 shares of the company’s stock valued at $34,660,000 after acquiring an additional 112,272 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.